Company profilePharmaceutical#340 of 1,318 in Pakistan✓ No DRAP alerts

CANDID PHARMACEUTICALS

Pharmaceutical company · 52 brands · 55 molecules

Ranked #136 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

52 registered products 16 pharmaceutical brands 55 distinct molecules 0 DRAP alerts

Company overview

52
registered products
16
pharmaceutical brands
55
distinct molecules
1
therapeutic classes
0
DRAP alerts

CANDID PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 52 product registrations across 55 distinct molecules. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 2

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

SHROOQ PHARMACEUTICALS21 shared molecules
VALOR PHARMACEUTICALS19 shared molecules
IRZA PHARMA (PVT) LTD.19 shared molecules
Albro Pharmaceuticals18 shared molecules
NEUTRO PHARMA (PVT) LTD.18 shared molecules

Get the full profile for CANDID

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.